Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study. - Kao CM; Chen YJ; Chen YM; Chen DY; Chen HH (Therapeutic advances in musculoskeletal disease, 2025)